Found: 12
Select item for more details and to access through your institution.
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2021, v. 147, n. 12, p. 3665, doi. 10.1007/s00432-021-03602-w
- By:
- Publication type:
- Article
Rivaroxaban Versus Low-molecular-weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary Cancer.
- Published in:
- In Vivo, 2020, v. 34, n. 2, p. 829, doi. 10.21873/invivo.11845
- By:
- Publication type:
- Article
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib.
- Published in:
- Hepatology Research, 2021, v. 51, n. 7, p. 796, doi. 10.1111/hepr.13669
- By:
- Publication type:
- Article
Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis.
- Published in:
- Liver International, 2021, v. 41, n. 6, p. 1389, doi. 10.1111/liv.14817
- By:
- Publication type:
- Article
Regorafenib in patients with advanced Child‐Pugh B hepatocellular carcinoma: A multicentre retrospective study.
- Published in:
- Liver International, 2020, v. 40, n. 10, p. 2544, doi. 10.1111/liv.14573
- By:
- Publication type:
- Article
Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events.
- Published in:
- Liver International, 2020, v. 40, n. 9, p. 2263, doi. 10.1111/liv.14496
- By:
- Publication type:
- Article
Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis.
- Published in:
- Liver Cancer (2235-1795), 2020, v. 9, n. 5, p. 613, doi. 10.1159/000508901
- By:
- Publication type:
- Article
Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 5, p. 1745, doi. 10.1002/cam4.3783
- By:
- Publication type:
- Article
Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma.
- Published in:
- Cancer Management & Research, 2021, v. 13, p. 4241, doi. 10.2147/CMAR.S309092
- By:
- Publication type:
- Article
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 5, p. 653, doi. 10.1007/s11523-021-00834-1
- By:
- Publication type:
- Article
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.
- Published in:
- 2021
- By:
- Publication type:
- corrected article